PI3K isoforms in cell signalling and vesicle trafficking (original) (raw)

• Herman, P. K. & Emr, S. D. Characterization of VPS34, a gene required for vacuolar protein sorting and vacuole segregation in Saccharomyces cerevisiae. Mol. Cell. Biol. 10, 6742–6754 (1990).
  CAS PubMed PubMed Central Google Scholar
• Balla, T. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol. Rev. 93, 1019–1137 (2013).
  CAS PubMed PubMed Central Google Scholar
• Schink, K. O., Tan, K.-W. & Stenmark, H. Phosphoinositides in control of membrane dynamics. Annu. Rev. Cell Dev. Biol. 32, 143–171 (2016).
  CAS PubMed Google Scholar
• Zvelebil, M. J. et al. Structural and functional diversity of phosphoinositide 3-kinases. Philos. Trans. R. Soc. B 351, 217–223 (1996).
  CAS Google Scholar
• MacDougall, L. K., Domin, J. & Waterfield, M. D. A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction. Curr. Biol. 5, 1404–1415 (1995).
  CAS PubMed Google Scholar
• Vanhaesebroeck, B., Leevers, S. J., Panayotou, G. & Waterfield, M. D. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 22, 267–272 (1997).
  CAS PubMed Google Scholar
• Domin, J. & Waterfield, M. D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 410, 91–95 (1997).
  CAS PubMed Google Scholar
• Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B. & Foukas, L. C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30, 194–204 (2005).
  CAS PubMed Google Scholar
• Gulluni, F. et al. Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2α scaffolding function. Cancer Cell 32, 444–459 (2017).This study provides the first evidence for a scaffolding function of a class II PI3K that is independent of its catalytic activity.
  CAS PubMed Google Scholar
• Devereaux, K. et al. Regulation of mammalian autophagy by class II and III PI 3-kinases through PI3P synthesis. PLOS ONE 8, e76405 (2013).
  CAS PubMed PubMed Central Google Scholar
• Hirsch, E., Braccini, L., Ciraolo, E., Morello, F. & Perino, A. Twice upon a time: PI3K’s secret double life exposed. Trends Biochem. Sci. 34, 244–248 (2009).
  CAS PubMed Google Scholar
• Burke, J. E. Structural basis for regulation of phosphoinositide kinases and their involvement in human disease. Mol. Cell 71, 653–673 (2018).
  CAS PubMed Google Scholar
• Burke, J. E. & Williams, R. L. Synergy in activating class I PI3Ks. Trends Biochem. Sci. 40, 88–100 (2015).
  CAS PubMed Google Scholar
• Dornan, G. L. & Burke, J. E. Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in class IA phosphoinositide 3-kinases. Front. Immunol. 9, 575 (2018).
  PubMed PubMed Central Google Scholar
• Fruman, D. A. et al. The PI3K pathway in human disease. Cell 170, 605–635 (2017).
  CAS PubMed PubMed Central Google Scholar
• Vanhaesebroeck, B., Whitehead, M. A. & Pineiro, R. Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J. Mol. Med. 94, 5–11 (2016).
  CAS PubMed Google Scholar
• Hawkins, P. T. & Stephens, L. R. PI3K signalling in inflammation. Biochim. Biophys. Acta 1851, 882–897 (2015).
  CAS PubMed Google Scholar
• Stark, A. K., Sriskantharajah, S., Hessel, E. M. & Okkenhaug, K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr. Opin. Pharmacol. 23, 82–91 (2015).
  CAS PubMed PubMed Central Google Scholar
• Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140–156 (2014).
  CAS PubMed PubMed Central Google Scholar
• Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7–24 (2015).
  CAS PubMed PubMed Central Google Scholar
• Janku, F., Yap, T. A. & Meric-Bernstam, F. Targeting the PI3K pathway in cancer: are we making headway? Nat. Rev. Clin. Oncol. 15, 273–291 (2018).
  CAS PubMed Google Scholar
• Mayer, I. A. & Arteaga, C. L. The PI3K/AKT pathway as a target for cancer treatment. Annu. Rev. Med. 67, 11–28 (2016).
  CAS PubMed Google Scholar
• Tsolakos, N. et al. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. Proc. Natl Acad. Sci. USA 115, 12176–12181 (2018).This study provides an in-depth quantitative assessment of the endogenous levels of the class IA PI3K catalytic and regulatory subunits in mouse tissues and cells and their interaction with each other and with receptors under basal and stimulated conditions.
  CAS PubMed PubMed Central Google Scholar
• Vadas, O. et al. Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc. Natl Acad. Sci. USA 110, 18862–18867 (2013).
  CAS PubMed PubMed Central Google Scholar
• Fritsch, R. & Downward, J. SnapShot: class I PI3K isoform signaling. Cell 154, 940–940 (2013).
  CAS PubMed Google Scholar
• Fritsch, R. et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153, 1050–1063 (2013).
  CAS PubMed PubMed Central Google Scholar
• Dbouk, H. A. et al. G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness. Sci. Signal. 5, ra89 (2012).
  PubMed PubMed Central Google Scholar
• Salamon, R. S. et al. Identification of the Rab5 binding site in p110β: assays for PI3Kβ binding to Rab5. Methods Mol. Biol. 1298, 271–281 (2015).
  CAS PubMed PubMed Central Google Scholar
• Bresnick, A. R. & Backer, J. M. PI3Kβ — a versatile transducer for GPCR, RTK and small GTPase signaling. Endocrinology 160, 536–555 (2019).
  PubMed PubMed Central Google Scholar
• Malek, M. et al. PTEN regulates PI(3,4)P2 signaling downstream of class I PI3K. Mol. Cell 68, 566–580 (2017).This study demonstrates that PTEN is not only a lipid phosphatase for PtdIns(3,4,5)P 3 as was previously thought but also uses PtdIns(3,4)P 2 as a substrate to convert it into PtdIns4P.
  CAS PubMed PubMed Central Google Scholar
• Lee, Y. R., Chen, M. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat. Rev. Mol. Cell. Biol. 19, 547–562 (2018).
  CAS PubMed Google Scholar
• Costa, C. & Hirsch, E. in Current Topics in Microbiology and Immunology (eds Rommel, C., Vanhaesebroeck, B. & Vogt, P.) 171–181 (Springer, 2010).
• Ito, Y., Hart, J. R. & Vogt, P. K. Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases — potentially novel therapeutic targets. Expert Opin. Ther. Targets 22, 869–877 (2018).
  CAS PubMed PubMed Central Google Scholar
• Takiar, V., Ip, C. K., Gao, M., Mills, G. B. & Cheung, L. W. Neomorphic mutations create therapeutic challenges in cancer. Oncogene 36, 1607–1618 (2017).
  CAS PubMed Google Scholar
• Marshall, J. D. S., Whitecross, D. E., Mellor, P. & Anderson, D. H. Impact of p85α alterations in cancer. Biomolecules 9, 29 (2019).
  PubMed Central Google Scholar
• Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell. Biol. 11, 329–341 (2010).
  CAS PubMed Google Scholar
• Li, H. & Marshall, A. J. Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: a distinct branch of PI3K signaling. Cell. Signal. 27, 1789–1798 (2015).
  PubMed Google Scholar
• Hawkins, P. T. & Stephens, L. R. Emerging evidence of signalling roles for PI(3,4)P2 in class I and II PI3K-regulated pathways. Biochem. Soc. Trans. 44, 307–314 (2016).
  CAS PubMed Google Scholar
• Isakoff, S. J. et al. Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J. 17, 5374–5387 (1998).
  CAS PubMed PubMed Central Google Scholar
• Zhang, P., Wang, Y., Sesaki, H. & Iijima, M. Proteomic identification of phosphatidylinositol (3,4,5) triphosphate-binding proteins in Dictyostelium discoideum. Proc. Natl Acad. Sci. USA 107, 11829–11834 (2010).
  CAS PubMed PubMed Central Google Scholar
• Park, W. S. et al. Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. Mol. Cell 30, 381–392 (2008).
  CAS PubMed PubMed Central Google Scholar
• Krugmann, S. et al. Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. Mol. Cell 9, 95–108 (2002).
  CAS PubMed Google Scholar
• Chen, C. L., Wang, Y., Sesaki, H. & Iijima, M. Myosin I links PIP3 signaling to remodeling of the actin cytoskeleton in chemotaxis. Sci. Signal. 5, ra10 (2012).
  PubMed PubMed Central Google Scholar
• Plantard, L. et al. PtdIns(3,4,5)P3 is a regulator of myosin-X localization and filopodia formation. J. Cell Sci. 123, 3525–3534 (2010).
  CAS PubMed Google Scholar
• Manning, B. D. & Toker, A. AKT/PKB signaling: navigating the network. Cell 169, 381–405 (2017).
  CAS PubMed PubMed Central Google Scholar
• Lien, E. C., Dibble, C. C. & Toker, A. PI3K signaling in cancer: beyond AKT. Curr. Opin. Cell Biol. 45, 62–71 (2017).
  CAS PubMed PubMed Central Google Scholar
• Dansen, T. B. & Burgering, B. M. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 18, 421–429 (2008).
  CAS PubMed Google Scholar
• Hornsveld, M., Dansen, T. B., Derksen, P. W. & Burgering, B. M. T. Re-evaluating the role of FOXOs in cancer. Semin. Cancer Biol. 50, 90–100 (2018).
  CAS PubMed Google Scholar
• Hedrick, S. M., Hess Michelini, R., Doedens, A. L., Goldrath, A. W. & Stone, E. L. FOXO transcription factors throughout T cell biology. Nat. Rev. Immunol. 12, 649–661 (2012).
  CAS PubMed Google Scholar
• Luo, C. T. & Li, M. O. Foxo transcription factors in T cell biology and tumor immunity. Semin. Cancer Biol. 50, 13–20 (2018).
  CAS PubMed PubMed Central Google Scholar
• Dummler, B. & Hemmings, B. A. Physiological roles of PKB/Akt isoforms in development and disease. Biochem. Soc. Trans. 35, 231–235 (2007).
  CAS PubMed Google Scholar
• Toker, A. & Marmiroli, S. Signaling specificity in the Akt pathway in biology and disease. Adv. Biol. Regul. 55, 28–38 (2014).
  CAS PubMed Google Scholar
• Chin, Y. R. & Toker, A. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol. Cell 38, 333–344 (2010).This is one of the first reports of AKT isoform substrate specificity in cells.
  CAS PubMed PubMed Central Google Scholar
• Liu, S. L. et al. Quantitative lipid imaging reveals a new signaling function of phosphatidylinositol-3,4-bisphophate: isoform- and site-specific activation of Akt. Mol. Cell 71, 1092–1104 (2018).This study provides a molecular mechanism, based on AKT-isoform-selective endocytosis, for AKT isoform substrate specificity in cells.
  CAS PubMed PubMed Central Google Scholar
• Li Chew, C. et al. In vivo role of INPP4B in tumor and metastasis suppression through regulation of PI3K–AKT signaling at endosomes. Cancer Discov. 5, 740–751 (2015).
  CAS PubMed Google Scholar
• Walz, H. A. et al. Isoform-specific regulation of Akt signaling by the endosomal protein WDFY2. J. Biol. Chem. 285, 14101–14108 (2010).
  CAS PubMed PubMed Central Google Scholar
• Braccini, L. et al. PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat. Commun. 6, 7400–7400 (2015).This is the first description of a role of the liver-specific class II isoform PI3KC2γ, based on endosomal PtdIns(3,4)P 2 production.
  CAS PubMed Google Scholar
• Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728–1731 (2001).
  CAS PubMed Google Scholar
• Choi, S. et al. Agonist-stimulated phosphatidylinositol-3,4,5-trisphosphate generation by scaffolded phosphoinositide kinases. Nat. Cell Biol. 18, 1324–1335 (2016).
  CAS PubMed PubMed Central Google Scholar
• Foukas, L. C. et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366–370 (2006).
  CAS PubMed Google Scholar
• Knight, Z. A. et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733–747 (2006).
  CAS PubMed PubMed Central Google Scholar
• Nylander, S. et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J. Thromb. Haemost. 10, 2127–2136 (2012).
  CAS PubMed Google Scholar
• Mateo, J. et al. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 23, 5981–5992 (2017).
  CAS PubMed Google Scholar
• Graupera, M. et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 453, 662–666 (2008).
  CAS PubMed Google Scholar
• Ciraolo, E. et al. Essential role of the p110β subunit of phosphoinositide 3-OH kinase in male fertility. Mol. Biol. Cell 21, 704–711 (2010).
  CAS PubMed PubMed Central Google Scholar
• Guillermet-Guibert, J. et al. Novel role for p110β PI 3-kinase in male fertility through regulation of androgen receptor activity in Sertoli cells. PLOS Genet. 11, e1005304 (2015).
  PubMed PubMed Central Google Scholar
• Gratacap, M. P. et al. Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions. Adv. Enzyme Regul. 51, 106–116 (2011).
  CAS PubMed Google Scholar
• So, L. & Fruman, D. A. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem. J. 442, 465–481 (2012).
  CAS PubMed Google Scholar
• Ruckle, T., Schwarz, M. K. & Rommel, C. PI3Kγ inhibition: towards an ‘aspirin of the 21st century’? Nat. Rev. Drug Discov. 5, 903–918 (2006).
  PubMed Google Scholar
• Perino, A. et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. Mol. Cell 42, 84–95 (2011).
  CAS PubMed PubMed Central Google Scholar
• Damilano, F. et al. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase γ activity in pressure overload-induced cardiac failure. Circulation 123, 391–399 (2011).
  CAS PubMed Google Scholar
• Eickholt, B. J. et al. Control of axonal growth and regeneration of sensory neurons by the p110δ PI 3-kinase. PLOS ONE 2, e869 (2007).
  PubMed PubMed Central Google Scholar
• Law, A. J. et al. Neuregulin 1–ErbB4–PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proc. Natl Acad. Sci. USA 109, 12165–12170 (2012).
  CAS PubMed PubMed Central Google Scholar
• Bartok, B., Hammaker, D. & Firestein, G. S. Phosphoinositide 3-kinase δ regulates migration and invasion of synoviocytes in rheumatoid arthritis. J. Immunol. 192, 2063–2070 (2014).
  CAS PubMed Google Scholar
• Whitehead, M. A., Bombardieri, M., Pitzalis, C. & Vanhaesebroeck, B. Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter. Biochem. J. 443, 857–867 (2012).
  CAS PubMed Google Scholar
• Sawyer, C. et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110δ. Cancer Res. 63, 1667–1675 (2003).
  CAS PubMed Google Scholar
• Goulielmaki, E. et al. Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death Dis. 9, 678 (2018).
  PubMed PubMed Central Google Scholar
• Ko, E. et al. PI3Kδ is a new therapeutic target in hepatocellular carcinoma. Hepatology 68, 2285–2300 (2018).
  CAS PubMed Google Scholar
• Yue, D. & Sun, X. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma. Cell Death Dis. 9, 935 (2018).
  PubMed PubMed Central Google Scholar
• Papakonstanti, E. A. et al. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J. Cell Sci. 121, 4124–4133 (2008).
  CAS PubMed Google Scholar
• Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A. & Vanhaesebroeck, B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl Acad. Sci. USA 107, 11381–11386 (2010).
  CAS PubMed PubMed Central Google Scholar
• Arafeh, R. & Samuels, Y. PIK3CA in cancer: the past 30 years. >Semin. Cancer Biol. https://doi.org/10.1016/j.semcancer.2019.02.002 (2019).
• Burke, J. E., Perisic, O., Masson, G. R., Vadas, O. & Williams, R. L. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc. Natl Acad. Sci. USA 109, 15259–15264 (2012).This study provides an in-depth assessment of how cancer-associated mutations in PIK3CA affect the biochemical characteristics of the p110α–p85α complex.
  CAS PubMed PubMed Central Google Scholar
• Oda, K., Stokoe, D., Taketani, Y. & McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65, 10669–10673 (2005).
  CAS PubMed Google Scholar
• Madsen, R. R. et al. Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner. Proc. Natl Acad. Sci. USA 116, 8380–8389 (2019). This study shows that homozygous but not heterozygous mutation of PIK3CA induces broad biological effects in human induced pluripotent stem cells, and provides evidence that many PIK3CA -mutant tumours either show homozygous mutation in this gene or carry additional activating genetic lesions in the PI3K pathway.
• Hyman, D. M. et al. AKT inhibition in solid tumors with AKT1 mutations. J. Clin. Oncol. 35, 2251–2259 (2017).
  CAS PubMed PubMed Central Google Scholar
• Berenjeno, I. M. et al. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nat. Commun. 8, 1773 (2017).
  PubMed PubMed Central Google Scholar
• Gerstung, M. et al. The evolutionary history of 2,658 cancers. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/161562v3 (2019).
• Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
  CAS PubMed Google Scholar
• Morris, J. Z., Tissenbaum, H. A. & Ruvkun, G. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382, 536–539 (1996).
  CAS PubMed Google Scholar
• Bosch, A. et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci. Transl. Med. 7, 283ra51 (2015).
  PubMed PubMed Central Google Scholar
• Toska, E. et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355, 1324–1330 (2017).The studies reported in Bosch et al. (2015) and Toska et al. (2017) uncover mechanisms of how PIK3CA mutation modulates oestrogen hormone responsiveness in breast cancer cell lines, and together with other studies form the basis of the ongoing phase III trials of PI3Kα inhibitors with hormone therapy.
  CAS PubMed PubMed Central Google Scholar
• Koren, S. & Bentires-Alj, M. Tackling resistance to PI3K inhibition by targeting the epigenome. Cancer Cell 31, 616–618 (2017).
  CAS PubMed Google Scholar
• Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575–586 (2011).
  CAS PubMed PubMed Central Google Scholar
• Zhu, Q. et al. Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27, 4569–4579 (2008).
  CAS PubMed PubMed Central Google Scholar
• Jiang, X., Chen, S., Asara, J. M. & Balk, S. P. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110β and p110δ catalytic subunits. J. Biol. Chem. 285, 14980–14989 (2010).
  CAS PubMed PubMed Central Google Scholar
• Marques, R. B. et al. High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. Eur. Urol. 67, 1177–1185 (2015).
  CAS PubMed Google Scholar
• Rinnerthaler, G., Gampenrieder, S. P. & Greil, R. ASCO 2018 highlights: metastatic breast cancer. Memo 11, 276–279 (2018).
  PubMed PubMed Central Google Scholar
• Kaneda, M. M. et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
  CAS PubMed PubMed Central Google Scholar
• De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539, 443–447 (2016).
  PubMed PubMed Central Google Scholar
• Ali, K. et al. Inactivation of PI(3)K p110δ breaks regulatory T cell-mediated immune tolerance to cancer. Nature 510, 407–411 (2014).The studies reported in Kaneda et al. (2016), De Henau et al. (2016) and Ali et al. (2014) demonstrate the potential of drugs targeting leukocyte-expressed PI3Kγ and PI3Kδ in cancer immunotherapy.
  CAS PubMed PubMed Central Google Scholar
• Abu-Eid, R. et al. Selective inhibition of regulatory T cells by targeting the PI3K–Akt pathway. Cancer Immunol. Res. 2, 1080–1089 (2014).
  CAS PubMed PubMed Central Google Scholar
• Ahmad, S. et al. Differential PI3Kδ signaling in CD4+ T cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Cancer Res. 77, 1892–1904 (2017).
  CAS PubMed Google Scholar
• Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728–732 (2017).
  CAS PubMed PubMed Central Google Scholar
• Okkenhaug, K., Graupera, M. & Vanhaesebroeck, B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 6, 1090–1105 (2016).
  CAS PubMed PubMed Central Google Scholar
• Burger, J. A. & Wiestner, A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat. Rev. Cancer 18, 148–167 (2018).
  CAS PubMed Google Scholar
• Brown, J. R. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Semin. Oncol. 43, 260–264 (2016).
  CAS PubMed Google Scholar
• Ho, L. K., Liu, D., Rozycka, M., Brown, R. A. & Fry, M. J. Identification of four novel human phosphoinositide 3-kinases defines a multi-isoform subfamily. Biochem. Biophys. Res. Commun. 235, 130–137 (1997).
  CAS PubMed Google Scholar
• Falasca, M. et al. The role of phosphoinositide 3-kinase C2α in insulin signaling. J. Biol. Chem. 282, 28226–28236 (2007).
  CAS PubMed Google Scholar
• Leibiger, B. et al. Insulin-feedback via PI3K-C2α activated PKBα/Akt1 is required for glucose-stimulated insulin secretion. FASEB J. 24, 1824–1837 (2010).
  CAS PubMed Google Scholar
• Maffucci, T. et al. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J. Cell Biol. 169, 789–799 (2005).
  CAS PubMed PubMed Central Google Scholar
• Bridges, D. et al. Phosphatidylinositol 3,5-bisphosphate plays a role in the activation and subcellular localization of mechanistic target of rapamycin 1. Mol. Biol. Cell 23, 2955–2962 (2012).
  CAS PubMed PubMed Central Google Scholar
• Marat, A. L. & Haucke, V. Phosphatidylinositol 3-phosphates—at the interface between cell signalling and membrane traffic. EMBO J. 35, 561–579 (2016).
  CAS PubMed PubMed Central Google Scholar
• Gulluni, F., De Santis, M. C., Margaria, J. P., Martini, M. & Hirsch, E. Class II PI3K functions in cell biology and disease. Trends Cell Biol. 29, 339–359 (2019).
  CAS PubMed Google Scholar
• Wang, H. et al. Autoregulation of class II alpha PI3K activity by its lipid-binding PX-C2 domain module. Mol. Cell 71, 343–351 (2018).This is the first description of a regulatory mechanism for a class II PI3K.
  CAS PubMed Google Scholar
• Gaidarov, I., Smith, M. E., Domin, J. & Keen, J. H. The class II phosphoinositide 3-kinase C2α is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell 7, 443–449 (2001).
  CAS PubMed Google Scholar
• Posor, Y. et al. Spatiotemporal control of endocytosis by phosphatidylinositol-3, 4-bisphosphate. Nature 499, 233–237 (2013).This study provided evidence of PtdIns(3,4)P 2 formation by a class II PI3K and how this regulates clathrin-mediated endocytosis.
  CAS PubMed Google Scholar
• Stahelin, R. V. et al. Structural and membrane binding analysis of the Phox homology domain of phosphoinositide 3-kinase-C2α. J. Biol. Chem. 281, 39396–39406 (2006).
  CAS PubMed Google Scholar
• Chen, K. E., Tillu, V. A., Chandra, M. & Collins, B. M. Molecular basis for membrane recruitment by the PX and C2 domains of class II phosphoinositide 3-kinase-C2α. Structure 26, 1–14 (2018).
  Google Scholar
• Pirola, L. et al. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase α (PI3Kα). Functions of lipid kinase-deficient PI3Kα in signaling. J. Biol. Chem. 276, 21544–21554 (2001).
  CAS PubMed Google Scholar
• Goulden, B. D. et al. A high-avidity biosensor reveals plasma membrane PI(3,4)P2 is predominantly a class I PI3K signaling product. J. Cell Biol. 218, 1066–1079 (2018).
  PubMed Google Scholar
• Laketa, V. et al. Membrane-permeant phosphoinositide derivatives as modulators of growth factor signaling and neurite outgrowth. Chem. Biol. 16, 1190–1196 (2009).
  CAS PubMed Google Scholar
• Marat, A. L. et al. mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate. Science 356, 968–968 (2017).This study reveals a new link between class II PI3Ks and mTORC1 regulation.
  CAS PubMed Google Scholar
• Campa, C. C. et al. Rab11 activity and PtdIns(3)P turnover removes recycling cargo from endosomes. Nat. Chem. Biol. 14, 801–810 (2018).
  CAS PubMed Google Scholar
• Franco, I. et al. PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. Dev. Cell 28, 647–658 (2014).
  CAS PubMed PubMed Central Google Scholar
• Campa, C. C., Franco, I. & Hirsch, E. PI3K-C2α: one enzyme for two products coupling vesicle trafficking and signal transduction. FEBS Lett. 589, 1552–1558 (2015).
  CAS PubMed Google Scholar
• Nakatsu, F. et al. PtdIns4P synthesis by PI4KIIIα at the plasma membrane and its impact on plasma membrane identity. J. Cell Biol. 199, 1003–1016 (2012).
  CAS PubMed PubMed Central Google Scholar
• Hammond, G. R. V. et al. PI4P and PI(4,5)P2 are essential but independent lipid determinants of membrane identity. Science 727, 2–6 (2012).
  Google Scholar
• Saheki, Y. et al. Control of plasma membrane lipid homeostasis by the extended synaptotagmins. Nat. Cell Biol. 18, 504–515 (2016).
  CAS PubMed PubMed Central Google Scholar
• Booth, D. G., Hood, F. E., Prior, I. A. & Royle, S. J. A. TACC3/ch-TOG/clathrin complex stabilises kinetochore fibres by inter-microtubule bridging. EMBO J. 30, 906–919 (2011).
  CAS PubMed PubMed Central Google Scholar
• Jean, S., Cox, S., Schmidt, E. J., Robinson, F. L. & Kiger, A. Sbf/MTMR13 coordinates PI(3)P and Rab21 regulation in endocytic control of cellular remodeling. Mol. Biol. Cell 23, 2723–2740 (2012).
  CAS PubMed PubMed Central Google Scholar
• Hauswirth, A. G. et al. A postsynaptic PI3K-cII dependent signaling controller for presynaptic homeostatic plasticity. eLife 7, e31535 (2018).
  PubMed PubMed Central Google Scholar
• Velichkova, M. et al. Drosophila Mtm and class II PI3K coregulate a PI(3)P pool with cortical and endolysosomal functions. J. Cell Biol. 190, 407–425 (2010).
  CAS PubMed PubMed Central Google Scholar
• Posor, Y., Eichhorn-Grünig, M. & Haucke, V. Phosphoinositides in endocytosis. Biochim. Biophys. Acta 1851, 794–804 (2014).
  PubMed Google Scholar
• Schöneberg, J. et al. Lipid-mediated PX-BAR domain recruitment couples local membrane constriction to endocytic vesicle fission. Nat. Commun. 8, 15873 (2017).
  PubMed PubMed Central Google Scholar
• Almeida-Souza, L. et al. A flat BAR protein promotes actin polymerization at the base of clathrin-coated pits. Cell 174, 325–337 (2018).
  CAS PubMed PubMed Central Google Scholar
• He, K. et al. Dynamics of phosphoinositide conversion in clathrin-mediated endocytic traffic. Nature 552, 410–414 (2017).
  CAS PubMed PubMed Central Google Scholar
• Aki, S., Yoshioka, K., Okamoto, Y., Takuwa, N. & Takuwa, Y. Phosphatidylinositol 3-kinase class II α-isoform PI3K-C2α is required for transforming growth factor β-induced Smad signaling in endothelial cells. J. Biol. Chem. 290, 6086–6105 (2015).
  CAS PubMed PubMed Central Google Scholar
• Alliouachene, S. et al. Inactivation of the class II PI3K-C2β potentiates insulin signaling and sensitivity. Cell Rep. 13, 1881–1894 (2015).
  CAS PubMed PubMed Central Google Scholar
• Korolchuk, V. I. et al. Lysosomal positioning coordinates cellular nutrient responses. Nat. Cell Biol. 13, 453–460 (2011).
  CAS PubMed PubMed Central Google Scholar
• Katso, R. M. et al. Phosphoinositide 3-kinase C2β regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol. Biol. Cell 17, 3729–3744 (2006).
  CAS PubMed PubMed Central Google Scholar
• Domin, J. et al. The class II phosphoinositide 3-kinase PI3K-C2β regulates cell migration by a PtdIns(3)P dependent mechanism. J. Cell. Physiol. 205, 452–462 (2005).
  CAS PubMed Google Scholar
• Yoshioka, K. et al. Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat. Med. 18, 1560–1569 (2012).This study demonstrated that homozygous knockout of Pik3c2a in mice causes embryonic lethality as a consequence of impaired angiogenesis.
  CAS PubMed Google Scholar
• Biswas, K. et al. Essential role of class II phosphatidylinositol-3-kinase-C2α in sphingosine 1-phosphate receptor-1-mediated signaling and migration in endothelial cells. J. Biol. Chem. 288, 2325–2339 (2013).
  CAS PubMed Google Scholar
• Kalaidzidis, I. et al. APPL endosomes are not obligatory endocytic intermediates but act as stable cargo-sorting compartments. J. Cell Biol. 211, 123–144 (2015).
  CAS PubMed PubMed Central Google Scholar
• Zoncu, R. et al. A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes. Cell 136, 1110–1121 (2009).
  CAS PubMed PubMed Central Google Scholar
• Cai, X. et al. Tripartite motif containing protein 27 negatively regulates CD4 T cells by ubiquitinating and inhibiting the class II PI3K-C2β. Proc. Natl Acad. Sci. USA 108, 20072–20077 (2011).
  CAS PubMed PubMed Central Google Scholar
• Srivastava, S. et al. The class II phosphatidylinositol 3 kinase C2β is required for the activation of the K+ channel KCa3.1 and CD4 T cells. Mol. Biol. Cell 20, 3783–3791 (2009).
  CAS PubMed PubMed Central Google Scholar
• Srivastava, S., Cai, X., Li, Z., Sun, Y. & Skolnik, E. Y. Phosphatidylinositol-3-kinase C2 and TRIM27 function to positively and negatively regulate IgE receptor activation of mast cells. Mol. Cell. Biol. 32, 3132–3139 (2012).
  CAS PubMed PubMed Central Google Scholar
• Srivastava, S., Li, Z. & Skolnik, E. Y. Phosphatidlyinositol-3-kinase C2 beta (PI3KC2β) is a potential new target to treat IgE mediated disease. PLOS ONE 12, e0183474 (2017).
  PubMed PubMed Central Google Scholar
• Falasca, M. et al. Class II phosphoinositide 3-kinases as novel drug targets. J. Med. Chem. 60, 47–65 (2017).
  CAS PubMed Google Scholar
• Alliouachene, S. et al. Inactivation of class II PI3K-C2α induces leptin resistance, age-dependent insulin resistance and obesity in male mice. Diabetologia 59, 1503–1512 (2016).
  CAS PubMed PubMed Central Google Scholar
• Mountford, J. K. et al. The class II PI 3-kinase, PI3KC2α, links platelet internal membrane structure to shear-dependent adhesive function. Nat. Commun. 6, 6535 (2015).
  CAS PubMed Google Scholar
• Valet, C. et al. Essential role of class II PI3K-C2α in platelet membrane morphology. Blood 126, 1128–1138 (2015).
  CAS PubMed Google Scholar
• Tiosano, D. Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction. PLOS Genet. 15, e1008088 (2019).
• Harada, K., Truong, A. B., Cai, T. & Khavari, P. A. The class II phosphoinositide 3-kinase C2β is not essential for epidermal differentiation. Mol. Cell. Biol. 25, 11122–11130 (2005).
  CAS PubMed PubMed Central Google Scholar
• Amoasii, L., Hnia, K. & Laporte, J. Myotubularin phosphoinositide phosphatases in human diseases. Curr. Top. Microbiol. Immunol. 362, 209–233 (2012).
  CAS PubMed Google Scholar
• Ketel, K. et al. A phosphoinositide conversion mechanism for exit from endosomes. Nature 529, 408–412 (2016).
  CAS PubMed Google Scholar
• Ribeiro, I., Yuan, L., Tanentzapf, G., Dowling, J. J. & Kiger, A. Phosphoinositide regulation of integrin trafficking required for muscle attachment and maintenance. PLOS Genet. 7, e1001295 (2011).
  CAS PubMed PubMed Central Google Scholar
• Sabha, N. et al. PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. J. Clin. Invest. 126, 3613–3625 (2016).
  PubMed PubMed Central Google Scholar
• Backer, J. The intricate regulation and complex functions of the class III phosphoinositide 3-kinase Vps34. Biochem. J. 473, 2251–2271 (2016).
  CAS PubMed Google Scholar
• Ktistakis, N. T. & Tooze, S. A. Digesting the expanding mechanisms of autophagy. Trends Cell Biol. 26, 624–635 (2016).
  CAS PubMed Google Scholar
• Stjepanovic, G., Baskaran, S., Lin, M. G. & Hurley, J. H. Unveiling the role of VPS34 kinase domain dynamics in regulation of the autophagic PI3K complex. Mol. Cell. Oncol. 4, e1367873 (2017).
  PubMed PubMed Central Google Scholar
• Russell, R. C. et al. ULK1 induces autophagy by phosphorylating beclin-1 and activating VPS34 lipid kinase. Nat. Cell Biol. 15, 741–750 (2013).
  CAS PubMed PubMed Central Google Scholar
• Rostislavleva, K. et al. Structure and flexibility of the endosomal Vps34 complex reveals the basis of its function on membranes. Science 350, aac7365 (2015).This study reports on the crystal structure of the yeast Vps34 complex II and documents how Vps34 complexes adapt to membrane curvature.
  PubMed PubMed Central Google Scholar
• Stjepanovic, G., Baskaran, S., Lin, M. G. & Hurley, J. H. Vps34 kinase domain dynamics regulate the autophagic PI 3-kinase complex. Mol. Cell 67, 528–534 (2017).This study reports on the series of conformational changes involved in the regulation of VPS34 lipid kinase activity.
  CAS PubMed PubMed Central Google Scholar
• Baskaran, S. et al. Architecture and dynamics of the autophagic phosphatidylinositol 3-kinase complex. eLife 3, e05115 (2014).
  PubMed Central Google Scholar
• Ohashi, Y., Tremel, S. & Williams, R. L. VPS34 complexes from a structural perspective. J. Lipid Res. 60, 229–241 (2018).
  PubMed PubMed Central Google Scholar
• Fan, W., Nassiri, A. & Zhong, Q. Autophagosome targeting and membrane curvature sensing by Barkor/Atg14(L). Proc. Natl Acad. Sci. USA 108, 7769–7774 (2011).This study reveals the requirement of the BATS domain of ATG14 for its localization to the autophagosome in vivo and for membrane association in vitro.
  CAS PubMed PubMed Central Google Scholar
• Miller, S. et al. Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science 327, 1638–1642 (2010).This study was the first to unveil the structure of VPS34 (from D. melanogaster ), providing new insights into its catalytic mechanism and the binding of VPS34 inhibitors.
  CAS PubMed PubMed Central Google Scholar
• Bago, R. et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem. J. 463, 413–427 (2014).
  CAS PubMed Google Scholar
• Dowdle, W. E. et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat. Cell Biol. 16, 1069–1079 (2014).
  CAS PubMed Google Scholar
• Ronan, B. et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat. Chem. Biol. 10, 1013–1019 (2014).The studies reported in Bago et al. (2014), Dowdle et al. (2014) and Ronan et al. (2014) were the first to report highly selective VPS34 inhibitors.
  CAS PubMed Google Scholar
• Bilanges, B. et al. Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism. Nat. Commun. 8, 1804 (2017).
  PubMed PubMed Central Google Scholar
• Honda, A. et al. Potent, selective, and orally bioavailable inhibitors of VPS34 provide chemical tools to modulate autophagy in vivo. ACS Med. Chem. Lett. 7, 72–76 (2016).
  CAS PubMed Google Scholar
• Pasquier, B. et al. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)- 3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. J. Med. Chem. 58, 376–400 (2015).
  CAS PubMed Google Scholar
• Malik, N. et al. Mechanism of activation of SGK3 by growth factors via the class 1 and class 3 PI3Ks. Biochem. J. 475, 117–135 (2018).
  CAS PubMed Google Scholar
• Bago, R. et al. The hVps34–SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. EMBO J. 35, 1902–1922 (2016).
  CAS PubMed PubMed Central Google Scholar
• Valet, C. et al. A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth. Blood 130, 2032–2042 (2017).
  CAS PubMed PubMed Central Google Scholar
• Kim, J. et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 152, 290–303 (2013).
  CAS PubMed PubMed Central Google Scholar
• Nemazanyy, I. et al. Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling. Nat. Commun. 6, 8283 (2015).
  CAS PubMed Google Scholar
• He, F. et al. Phosphatidylinositol-3-phosphate is light-regulated and essential for survival in retinal rods. Sci. Rep. 6, 26978 (2016).
  CAS PubMed PubMed Central Google Scholar
• Martinez, J. et al. Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat. Cell Biol. 17, 893–906 (2015).
  CAS PubMed PubMed Central Google Scholar
• Gasser, J. A. et al. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol. Cell 56, 595–607 (2014).
  CAS PubMed PubMed Central Google Scholar
• Ebner, M., Sinkovics, B., Szczygiel, M., Ribeiro, D. W. & Yudushkin, I. Localization of mTORC2 activity inside cells. J. Cell Biol. 216, 343–353 (2017).
  CAS PubMed PubMed Central Google Scholar
• Tessier, M. & Woodgett, J. R. Role of the Phox homology domain and phosphorylation in activation of serum and glucocorticoid-regulated kinase-3. J. Biol. Chem. 281, 23978–23989 (2006).
  CAS PubMed Google Scholar
• Vasudevan, K. M. et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21–32 (2009).
  CAS PubMed PubMed Central Google Scholar
• O’Farrell, F. et al. Class III phosphatidylinositol-3-OH kinase controls epithelial integrity through endosomal LKB1 regulation. Nat. Cell Biol. 19, 1412–1423 (2017).
  PubMed Google Scholar
• Juhasz, G. et al. The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in Drosophila. J. Cell Biol. 181, 655–666 (2008).
  CAS PubMed PubMed Central Google Scholar
• Yoon, M. S., Du, G., Backer, J. M., Frohman, M. A. & Chen, J. Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway. J. Cell Biol. 195, 435–447 (2011).
  CAS PubMed PubMed Central Google Scholar
• Nobukuni, T. et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl Acad. Sci. USA 102, 14238–14243 (2005).
  CAS PubMed PubMed Central Google Scholar
• Gulati, P. et al. Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab. 7, 456–465 (2008).
  CAS PubMed PubMed Central Google Scholar
• Byfield, M. P., Murray, J. T. & Backer, J. M. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280, 33076–33082 (2005).The studies reported in Nobukuni et al. (2005) and Byfield et al. (2005) were the first to report a link between VPS34 and mTORC1.
  CAS PubMed Google Scholar
• Jaber, N. et al. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc. Natl Acad. Sci. USA 109, 2003–2008 (2012).
  CAS PubMed PubMed Central Google Scholar
• Willinger, T. & Flavell, R. A. Canonical autophagy dependent on the class III phosphoinositide-3 kinase Vps34 is required for naive T cell homeostasis. Proc. Natl Acad. Sci. USA 109, 8670–8675 (2012).
  CAS PubMed PubMed Central Google Scholar
• Zhou, X., Takatoh, J. & Wang, F. The mammalian class 3 PI3K (PIK3C3) is required for early embryogenesis and cell proliferation. PLOS ONE 6, e16358 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kuma, A., Komatsu, M. & Mizushima, N. Autophagy-monitoring and autophagy-deficient mice. Autophagy 13, 1619–1628 (2017).
  CAS PubMed PubMed Central Google Scholar
• Rohatgi, R. A. et al. Beclin 1 regulates growth factor receptor signaling in breast cancer. Oncogene 34, 5352–5362 (2015).
  CAS PubMed PubMed Central Google Scholar
• Madsen, R. R., Vanhaesebroeck, B. & Semple, R. K. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol. Med. 24, 856–870 (2018).
  CAS PubMed PubMed Central Google Scholar
• Dyczynski, M. et al. Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to sunitinib. Cancer Lett. 435, 32–43 (2018).
  CAS PubMed Google Scholar
• Liu, X. et al. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B cell malignancies. Oncotarget 7, 53515–53525 (2016).
  PubMed PubMed Central Google Scholar
• Levy, J. M. M., Towers, C. G. & Thorburn, A. Targeting autophagy in cancer. Nat. Rev. Cancer 17, 528–542 (2017).
  CAS PubMed Google Scholar
• Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 169, 361–371 (2017).
  CAS PubMed Google Scholar
• Castillo, S. D., Baselga, E. & Graupera, M. PIK3CA mutations in vascular malformations. Curr. Opin. Hematol. 26, 170–178 (2019).
  Article PubMed Google Scholar
• Hare, L. M. et al. Heterozygous expression of the oncogenic Pik3caH1047R mutation during murine development results in fatal embryonic and extraembryonic defects. Dev. Biol. 404, 14–26 (2015).
  CAS PubMed Google Scholar
• Venot, Q. et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 558, 540–546 (2018).This clinical study shows that treatment with a low dose of a PI3Kα-selective inhibitor is well tolerated in human patients with PIK3CA -related overgrowth spectrum, reduces aberrant tissue overgrowth and leads to clinical benefit.
  CAS PubMed PubMed Central Google Scholar
• Semple, R. K. & Vanhaesebroeck, B. Lessons for cancer drug treatment from tackling a non-cancerous overgrowth syndrome. Nature 558, 523–525 (2018).
  CAS PubMed Google Scholar
• Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477–2488 (2014).
  CAS PubMed PubMed Central Google Scholar
• Hollander, M. C., Blumenthal, G. M. & Dennis, P. A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11, 289–301 (2011).
  CAS PubMed PubMed Central Google Scholar
• Yehia, L. & Eng, C. One gene, many endocrine and metabolic syndromes: PTEN-opathies and precision medicine. Endocr. Relat. Cancer 25, T121–T140 (2018).
  CAS PubMed Google Scholar
• Keppler-Noreuil, K. M., Parker, V. E., Darling, T. N. & Martinez-Agosto, J. A. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway and therapeutic strategies. Am. J. Med. Genet. C 172, 402–421 (2016).
  CAS Google Scholar
• Zak, M., Ledbetter, M. & Maertens, P. Infantile Lhermitte–Duclos disease treated successfully with rapamycin. J. Child Neurol. 32, 322–326 (2017).
  PubMed Google Scholar
• Marsh, D. J. et al. Rapamycin treatment for a child with germline PTEN mutation. Nat. Clin. Pract. Oncol. 5, 357–361 (2008).
  CAS PubMed Google Scholar
• Angulo, I. et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 342, 866–871 (2013).
  CAS PubMed PubMed Central Google Scholar
• Lucas, C. L. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat. Immunol. 15, 88–97 (2014).
  CAS PubMed Google Scholar
• Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M. & Okkenhaug, K. PI3Kdelta and primary immunodeficiencies. Nat. Rev. Immunol. 16, 702–714 (2016).
  CAS PubMed PubMed Central Google Scholar
• Michalovich, D. & Nejentsev, S. Activated PI3 kinase delta syndrome: from genetics to therapy. Front. Immunol. 9, 369 (2018).
  PubMed PubMed Central Google Scholar
• Coulter, T. I. et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J. Allergy Clin. Immunol. 139, 597–606 (2017).
  CAS PubMed PubMed Central Google Scholar
• Rao, V. K. et al. Effective “activated PI3Kdelta syndrome”-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood 130, 2307–2316 (2017).
  CAS PubMed PubMed Central Google Scholar
• Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214–226 (2008).
  CAS PubMed PubMed Central Google Scholar
• Yoon, M. S. et al. Rapid mitogenic regulation of the mTORC1 inhibitor, DEPTOR, by phosphatidic acid. Mol. Cell 58, 549–556 (2015).
  CAS PubMed PubMed Central Google Scholar
• Raiborg, C. et al. Repeated ER–endosome contacts promote endosome translocation and neurite outgrowth. Nature 520, 234–238 (2015).
  CAS PubMed Google Scholar
• Hong, Z. et al. PtdIns3P controls mTORC1 signaling through lysosomal positioning. J. Cell Biol. 216, 4217–4233 (2017).
  CAS PubMed PubMed Central Google Scholar
• Liang, C. et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat. Cell Biol. 10, 776–787 (2008).
  CAS PubMed PubMed Central Google Scholar
• Sun, Q., Westphal, W., Wong, K. N., Tan, I. & Zhong, Q. Rubicon controls endosome maturation as a Rab7 effector. Proc. Natl Acad. Sci. USA 107, 19338–19343 (2010).
  CAS PubMed PubMed Central Google Scholar
• Sun, Q. et al. The RUN domain of rubicon is important for hVps34 binding, lipid kinase inhibition, and autophagy suppression. J. Biol. Chem. 286, 185–191 (2011).
  CAS PubMed Google Scholar